Asked by: Naz Shah (Labour - Bradford West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the weekly data is on deaths as a result of covid-19 from October 2020 to date.
Answered by Jo Churchill
Public Health England (PHE) reports weekly numbers of deaths in England in people with a laboratory-confirmed positive COVID-19 test, who died within 28 days of the first positive specimen date. This data is reported in the weekly National Flu and COVID-19 Surveillance report, which is available at the following link:
https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports
PHE also reports the weekly proportion of these deaths by ethnic group. This is available in the weekly surveillance reports.
Asked by: Naz Shah (Labour - Bradford West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the weekly data is on deaths as a result of covid-19 from October 2020 to date, by ethnicity.
Answered by Jo Churchill
Public Health England (PHE) reports weekly numbers of deaths in England in people with a laboratory-confirmed positive COVID-19 test, who died within 28 days of the first positive specimen date. This data is reported in the weekly National Flu and COVID-19 Surveillance report, which is available at the following link:
https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports
PHE also reports the weekly proportion of these deaths by ethnic group. This is available in the weekly surveillance reports.
Asked by: Naz Shah (Labour - Bradford West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, on what date covid-19 tests were made available for people living in (a) retirement complexes and (b) sheltered accommodation; when rapid flow tests will be made to people living in those types of accommodation; and for what reasons people living in those accommodations have not been provided with the same access to testing as people living in care homes.
Answered by Helen Whately - Shadow Secretary of State for Work and Pensions
Staff or residents within retirement complexes and sheltered accommodation who are symptomatic are eligible for testing through the self-referral portal. We are expanding our testing capacity all the time and we now have capacity to test over 500,000 people a day. We have prioritised people who are most at risk from the effects of Covid-19, and we will continue to review our social care testing strategy for adult social care in light of the latest evidence and available capacity.
Asked by: Naz Shah (Labour - Bradford West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps have been taken to assess the effectiveness of (a) inhaled treatment for covid-19 and (b) trails carried out by Synairgen plc in Bradford Royal Infirmary and other hospitals.
Answered by Jo Churchill
The Department with the National Institute for Health Research (NIHR) has established a single United Kingdom-wide process which labels COVID-19 research with the most potential with Urgent Public Health (UPH) status. Any trials evaluating the effectiveness of inhaled treatments are subject to this same process.
National and international trials are monitored by the RAPID-C19 initiative, which aims to get treatments for COVID-19 to National Health Service patients quickly and safely. This process begins with scanning all trials for COVID-19 treatments. Any promising drugs will be identified for further review.
Synairgen have been requested to submit a formal submission to UK-CTAP and NIHR UPH for review, where the inhaled interferon beta-1, SGN001 will be reviewed by a panel of independent experts to assess if it will be suitable to be incorporated into the RECOVERY+ trial or an independent trial, for Phase III.
UK-CTAP is an independent COVID-19 Therapeutics Advisory Panel, which will advise on what treatments should be proposed for testing through RECOVERY+. As with all other therapeutic compounds in trial, progress of the effectiveness will continue to be monitored by the Chief Medical Officer, NIHR UPH and RAPID C-19.